Committee Chair Andrew Miller MP said:
“Many of the trials taking place today are unregistered and unpublished, meaning that the information that they generate remains invisible to both the scientific community and the public. This is unacceptable, undermining public trust, slowing the pace of medical advancement and potentially putting patients at risk.
We consider that all trials conducted on NHS treatments—and all other trials receiving public funding—should be prospectively registered and their results published in a scientific journal. While the focus should be on implementing this change for future trials, the Government must also do what it can to ensure that historic trials are registered and published, particularly where they have been publically funded.”
The Committee also asked the Government to take steps to facilitate greater sharing of the raw data generated during a trial. Andrew Miller explained:
“We are not in favour of the uncontrolled release of potentially sensitive patient data, even in anonymised form. However, raw trial data is currently underutilised and could be of significant scientific value if shared in a responsible and controlled way, with the knowledge and consent of patients.”
The Report also drew attention to the recent fall in the number of trials taking place in the UK, stating that the UK was a “particularly challenging” place in which to conduct a trial. It found that the need for multiple governance approvals from participating NHS organisations remained the biggest barrier to setting up a UK trial, but that lack of public awareness was also a key issue.
Andrew Miller stated:
“Clinical trials make a significant contribution to the UK economy and can provide patients with an important means of accessing the most exciting new treatments.
Unfortunately, the UK governance landscape means that researchers can struggle to get trials up and running in this country. Recruiting participants can also be a challenge, even though many patients welcome the opportunity to take part in a trial.
These problems are not insurmountable and we are confident that the Government is aware of the need to resolve them. But it is now time for the Government to translate its words into effective action.”
The Report called on the Government to take its recommendations into account in ongoing discussions regarding the revision of European clinical trials legislation and in its response to the European Medicines Agency’s consultation on the release of clinical trial data, which closes at the end of this month.